Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Ontology highlight
ABSTRACT: A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
DISEASE(S): Colon Cancer,Unresectable Or Metastatic Microsatellite Stable (mss) Solid Tumor Along With Microsatellite Stable (mss) Colon Cancer,Colonic Neoplasms,Solid Tumors
PROVIDER: 2287207 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA